Biotech Startups

0 investors

0 investors

SymbioCellTech develops a cell therapy called "Neo-Islets" intended to treat Type 1 Diabetes without daily insulin injections or immunosuppressive anti-rejection drugs. The company targets the estimated 16 million people living with Type 1 Diabetes.

0 investors

0 investors

0 investors

0 investors

SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.

0 investors

0 investors

TAO Synergies (Nasdaq: TAOX) is a publicly traded investment vehicle focused exclusively on Bittensor (TAO), a token for decentralized AI, which it accumulates and stakes to generate revenue. The company aims to give shareholders exposure to the decentralized AI ecosystem and deliver long-term capital appreciation.

0 investors

Synata Bio develops customizable technology solutions for hydrogen and carbon economies, enabling hard-to-abate industries to achieve decarbonization targets while reducing carbon emissions and creating value from waste resources.

0 investors

0 investors

0 investors

0 investors

0 investors

Syncromune develops SYNC-T, an investigational in situ personalized combination immunotherapy platform designed to treat metastatic solid tumors by synchronizing patient-specific tumor antigens with immune modulatory biologics. The company's lead candidate, SV-102, is in Phase 2 clinical trials for metastatic castration-resistant prostate cancer.

0 investors

0 investors

Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors

0 investors